• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.4335 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 60,486
    Open 0.4335
    Bid (Size) 0.4000 (20)
    Ask (Size) 0.4055 (26)
    Prev. Close 0.4335
    Today's Range 0.4335 - 0.4335
    52wk Range 0.3060 - 4.380
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
    Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status 
    Via News Direct
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
    The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    -62.95%
    -62.95%
    1 Month
    +23.89%
    +23.89%
    3 Month
    -42.96%
    -42.96%
    6 Month
    -54.62%
    -54.62%
    1 Year
    -85.00%
    -85.00%

    More News

    Read More
    Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
    From Mainz BioMed NV
    Via GlobeNewswire
    Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
    From Mainz BioMed NV
    Via GlobeNewswire
    Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Provides Half Year 2024 Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
    Via Benzinga
    Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
    Via News Direct
    Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
    Via News Direct
    Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Reports Results of 2024 Annual General Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
    From Mainz BioMed NV
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
    Via Benzinga
    Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
    From Mainz BioMed NV
    Via GlobeNewswire
    mRNA Is Promising A Breakthrough In Fighting Cancer
    Via Benzinga
    Exposures COVID-19
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.